168 related articles for article (PubMed ID: 24633918)
1. Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.
Yao M; Wang L; Dong Z; Qian Q; Shi Y; Yu D; Wang S; Zheng W; Yao D
Tumour Biol; 2014 Jun; 35(6):5857-68. PubMed ID: 24633918
[TBL] [Abstract][Full Text] [Related]
2. [Short hairpin RNA mediated glypican-3 silencing inhibits hepatoma cell invasiveness and disrupts molecular pathways of angiogenesis].
Yu DD; Yao M; Chen J; Wang L; Yan MJ; Gu X; Qiu LW; Dong ZZ; Yao DF; Lu SL
Zhonghua Gan Zang Bing Za Zhi; 2013 Jun; 21(6):452-8. PubMed ID: 24034848
[TBL] [Abstract][Full Text] [Related]
3. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.
Dong Z; Yao M; Wang L; Yang J; Yao D
Mini Rev Med Chem; 2014; 14(14):1183-93. PubMed ID: 25553423
[TBL] [Abstract][Full Text] [Related]
4. [Intervention of glypican-3 genetic transcription on anti-proliferative effect of hepatoma cells with high metastatic potentiality].
Yao M; Wang L; Shi Y; Qian Q; Yu D; Shi Y; Lu S; Yao D
Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(32):2544-8. PubMed ID: 25410930
[TBL] [Abstract][Full Text] [Related]
5. Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.
Yu D; Dong Z; Yao M; Wu W; Yan M; Yan X; Qiu L; Chen J; Sai W; Yao D
Tumour Biol; 2013 Apr; 34(2):661-8. PubMed ID: 23192642
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
Wang L; Yao M; Pan LH; Qian Q; Yao DF
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
[TBL] [Abstract][Full Text] [Related]
7. ZEB1 enhances Warburg effect to facilitate tumorigenesis and metastasis of HCC by transcriptionally activating PFKM.
Zhou Y; Lin F; Wan T; Chen A; Wang H; Jiang B; Zhao W; Liao S; Wang S; Li G; Xu Z; Wang J; Zhang J; Ma H; Lin D; Li Q
Theranostics; 2021; 11(12):5926-5938. PubMed ID: 33897890
[TBL] [Abstract][Full Text] [Related]
8. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of FoxM1 by siRNA interference decreases cell proliferation, induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro.
Wu QF; Liu C; Tai MH; Liu D; Lei L; Wang RT; Tian M; Lü Y
Acta Pharmacol Sin; 2010 Mar; 31(3):361-6. PubMed ID: 20154714
[TBL] [Abstract][Full Text] [Related]
10. A novel multifunctional gold nanorod-mediated and tumor-targeted gene silencing of GPC-3 synergizes photothermal therapy for liver cancer.
Liu Y; Tan M; Fang C; Chen X; Liu H; Feng Y; Zhang Y; Min W
Nanotechnology; 2021 Apr; 32(17):175101. PubMed ID: 33445163
[TBL] [Abstract][Full Text] [Related]
11. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
Sun CK; Chua MS; He J; So SK
Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
13. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma.
Yao M; Wang L; Fang M; Zheng W; Dong Z; Yao D
Biosci Trends; 2016 Nov; 10(5):337-343. PubMed ID: 27795482
[TBL] [Abstract][Full Text] [Related]
14. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma.
Shao L; Yu X; Han Q; Zhang X; Lu N; Zhang C
Oncoimmunology; 2022; 11(1):2010894. PubMed ID: 36524206
[TBL] [Abstract][Full Text] [Related]
15. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.
Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH
Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495
[TBL] [Abstract][Full Text] [Related]
16. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.
Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D
Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941
[TBL] [Abstract][Full Text] [Related]
17. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP.
Miao HL; Pan ZJ; Lei CJ; Wen JY; Li MY; Liu ZK; Qiu ZD; Lin MZ; Chen NP; Chen M
J Cell Biochem; 2013 Mar; 114(3):625-31. PubMed ID: 23060277
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
